The Column Group

David Goeddel and Peter Svennilson serve as managing partners and make investment decisions. Goeddel was the first scientist hired at Genentech and co-founded Tularik, while Svennilson brought European biotech financing relationships from prior ventures. The partnership operates without a separate investment committee structure visible to outsiders.

The firm originates most opportunities through its partners' academic relationships, particularly with university labs in the San Francisco Bay Area and select European institutions. It also forms companies internally by recruiting scientific founders around specific biological mechanisms, then placing its own operators as interim executives. This is distinct from firms that compete for pre-packaged deals through banker-led processes.

It is a venture capital firm structured as a traditional limited-partner fund manager, not a single family office. The firm raised a $510 million venture fund in 2012 from institutional and individual limited partners (per Bloomberg, 2012), and has raised additional funds since then.

The firm makes exclusively direct equity investments, primarily leading or co-leading early-stage rounds for its portfolio companies. It does not operate as a fund-of-funds and has no publicly disclosed allocation to other venture managers. Its model relies on concentrated position-building in company formation, not diversification across third-party funds.

The firm targets formation-stage and early-stage investments, typically Series A and B rounds, with initial commitments ranging from $20 million to $60 million. It occasionally participates in later rounds for existing portfolio companies. Seed-stage activity is less characteristic; the firm prefers to lead the first institutional round where it can influence board composition and management selection.

The firm concentrates almost exclusively on biotechnology, particularly platform drug discovery companies. It has no disclosed investments in medical devices, healthcare IT, or diagnostics, and does not pursue the health-tech or digital-health sectors. Its mandate excludes any non-life-science sector entirely.

The Column Group embeds its partners as founding CEOs, board chairs, and scientific founders of portfolio companies, going well beyond board observation rights. David Goeddel's role at Genentech as the first bench scientist informs a culture where investment partners participate in early-stage drug discovery decisions directly. This operational entanglement at formation is atypical, even among specialist biotech investors.